ImmuPharma plc (LON:IMM – Get Free Report) shares reached a new 52-week low on Tuesday. The stock traded as low as GBX 2.51 and last traded at GBX 2.80, with a volume of 2,026,019 shares changing hands. The stock had previously closed at GBX 2.60.
ImmuPharma Trading Up 7.7%
The company’s 50-day moving average is GBX 3.54 and its two-hundred day moving average is GBX 4.54. The firm has a market cap of £17.50 million, a P/E ratio of -3.37 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last posted its quarterly earnings data on Tuesday, September 15th. The company reported GBX (0.84) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 559.87%. Research analysts anticipate that ImmuPharma plc will post -339.00 EPS for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Recommended Stories
- Five stocks we like better than ImmuPharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
